Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017, Cold Spring Harbor Laboratory
To trace the cause of metastasis in pancreatic cancer, the CSHL team used cells sampled from six mice to grow paired sets of pancreatic organoids -- balls of cells that develop in 3-D culture. The mice had gene mutations that induced pancreatic ductal cancer. In each of the mice, normal pancreatic ductal cells were compared with cells from the same animals in three distinct stages: pre-malignant, malignant, and metastatic. In this way, the team was certain to be comparing "apples to apples." Experiments revealed that cancer cells became capable of metastasis via an epigenetic reprogramming of gene enhancers, reverting them to an earlier developmental state characterized by proliferation and increased mobility. Credit: Vakoc Lab, CSHL

Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power their ability to metastasize, or spread to distant sites in the body, newly published research reveals.

The research, appearing online today in Cell, provides strong evidence supporting this explanation of metastasis, which is the cause of most cancer deaths. It pertains specifically to cells involved in the most common form of cancer, called or PDA.

To one of the lead investigators, Associate Professor Christopher Vakoc of Cold Spring Harbor Laboratory (CSHL), the team's evidence of acquiring the ability to spread by "remembering" a developmental program dormant since their earliest days "means that every cell, in a sense, is like a loaded gun."

Experiments conducted by postdoctoral investigators Jae-Seok Roe and Chang-Il Hwang, respectively of the Vakoc and Tuveson labs at CSHL, sought to discover the still obscure mechanisms that enable cancer cells to become metastatic. They focused on cells of the pancreas, since almost every case of pancreatic cancer culminates in metastasis - and, sadly, early death. Only about 8% of patients are alive 5 years after diagnosis.

Although cancer is well understood to have genetic causes, the factors responsible for its ability to spread have eluded scientists. The Vakoc team's new results make a case for metastasis to have epigenetic roots. The team used pancreatic organoid technology developed in the lab of Professor David Tuveson, Director of CSHL's Cancer Center and Director of Research for the Lustgarten Foundation. Organoids enabled the team to compare normal pancreatic ductal cells in six mice with cells from the same animals in three distinct stages: premalignant, malignant, and metastatic. "Importantly, we were therefore comparing 'apples to apples,' which is so critical in trying to understand how cancer works," says Dr. Hwang.

"Formation of a tumor is driven by genetic events," says Dr. Roe, "but its ability to spread may not involve direct changes in the DNA sequence." This was borne out in their analysis of the pancreatic organoids. Compared with cells in non-cancerous and tumor-derived organoids, those in metastatic ones displayed an extraordinary number of alterations in regions called enhancers. These genome elements are present in all cells, and normally are used by cells to turn on genes. "We show that to metastasize, the cell has to change, in effect, its whole telecommunications network - its enhancers are being reprogrammed," Vakoc says.

The team tracked down the molecular agent whose increased activity causes the reprogramming. Called FOXA1, it is typically active early in a cell's life, but dormant later on. In cancer, the new research indicates, FOXA1 activity enables a cell to return to a developmentally primitive state - one in which the pancreas is being formed, and cells are multiplying and moving around, assuming the positions that characterize the maturing organ.

"What cells in pancreatic metastases are doing is remembering what it was like to be an embryo," Vakoc says. FOXA1 activation, inducing enhancer reprogramming that endows a cancer cell with metastatic properties, is an epigenetic mechanism, as opposed to a genetic one, that explains at least one mechanism of metastasis in this form of , and likely, other cancer types as well.

"It seems quite plausible from our results that reprogramming of enhancers enables , generally, to achieve metastatic competence," Vakoc says.

Explore further: Aspirin slows growth of colon, pancreatic tumor cells

More information: "Enhancer reprogramming promotes pancreatic cancer metastasis" appears online July 27, 2017 in Cell.

Related Stories

Aspirin slows growth of colon, pancreatic tumor cells

December 15, 2016
Researchers from Oregon Health and Science University and Oregon State University have found that aspirin may slow the spread of some types of colon and pancreatic cancer cells. The paper is published in the American Journal ...

3-D culture system for pancreatic cancer has potential to change therapeutic approaches

December 31, 2014
Pancreatic cancer is one of the most deadly forms of cancer, with only 6 percent of patients surviving five years after diagnosis. Today, Cold Spring Harbor Laboratory (CSHL) and The Lustgarten Foundation jointly announce ...

Protein found to play key role in the spread of pancreatic cancer

April 18, 2016
Researchers from the University of Liverpool working with colleagues from around the globe have found an explanation for how pancreatic cancer spreads to the liver. These findings potentially hold the key to stopping this ...

Mutations in gene promoters reveal specific pathway pathologies in pancreatic cancer

May 8, 2017
Over the last decade, it has made good sense to study the genetic drivers of cancer by sequencing a tiny portion of the human genome called the exome - the 2% of our three billion base pairs that "spell out" the 21,000 genes ...

Immune cells localized near pancreatic cancer cells have altered metabolism, could promote cancer

May 9, 2017
A diagnosis of pancreatic cancer is a virtual death sentence, with only 3 to 5 per cent of patients surviving beyond five years. A key reason that it has the lowest survival rate of all major cancers is that it readily spreads ...

Starving pancreatic cancer cells: Scientists identify potential pancreatic cancer target

October 17, 2016
Researchers have found that a protein called SLC6A14 is overexpressed by several fold in pancreatic tumors taken from patients and in cancerous pancreatic cells lines compared with normal pancreatic tissue or normal pancreatic ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.